Company Description
DayTwo uses microbiome data to change the outlook of chronic disease — starting with type 2 diabetes. DayTwo is the first fully science-based digital therapeutics platform with unrivaled microbiome IP, AI, and data sets to optimize precision nutrition for multiple chronic or metabolic conditions. Diabetes is sweeping through America, affecting more than 37 million US citizens and costing more than $237B in direct healthcare and over $90B in reduced productivity. Based on its proprietary technology and machine learning algorithm, DayTwo’s app can predict, before a person eats a meal, how that meal will impact the individual’s sugar level and can help individuals modify their intake to avoid or reduce sugar spikes. DayTwo’s solution was proven to materially reduce sugar level (HBA1C) and improve members’ health. The company has amassed the world’s largest library of deep sequencing microbiomic samples and data. DayTwo’s app leverages this huge trove of data using proprietary AI algorithms to provide a personalized nutrition program for each user. Its science is based on more than seven years of research and clinical studies at the Weizmann Institute, Mayo Clinic and other leading research centers, and has been published in leading peer-reviewed journals including Nature, Cell, and the American Journal of Clinical Nutrition. DayTwo is now expanding to the US, creating partnerships with major corporations and healthcare providers in a B2B2C model that helps their employees and dependents manage type 2 diabetes and other chronic diseases, cutting healthcare costs and increasing employee satisfaction and engagement. DayTwo’s service includes a microbiome sequencing procedure, the ability to use DayTwo’s user-friendly app, and provides members with personalized and professional support from a dietitian and health guide.
The details here are based on information received from, and verified solely by, the company.
